Palisade Bio获得加拿大卫生部批准,启动Pali-2108治疗纤维狭窄性克罗恩病的1B期临床试验

美股速递
Sep 05, 2025

Palisade Bio公司宣布,已获得加拿大卫生部的批准许可,将开展其候选药物Pali-2108针对纤维狭窄性克罗恩病(FSCD)的1B期临床试验。这一监管里程碑的达成,为该公司推进这一创新疗法的临床开发奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10